Early and continued asthma control up to week 24 in patients with severe, uncontrolled asthma treated with tezepelumab: Initial results of the real-world ASCENT study
{{output}}
Introduction: Tezepelumab has demonstrated efficacy in patients with severe, uncontrolled asthma in randomized controlled trials (RCTs). Real-world studies assessing patient-reported outcomes are required to complement RCT findin... ...
